Kinex News
Back to headlines
December 30, 2008
KXO2 will be developed to treat brain cancer
Kinex Pharmaceuticals has selected KXO2; a compound that will be developed for brain cancer. The orally active compound has demonstrated extraordinary activity in a mouse glioblastoma model. When benchmarked against Temodar, a standard drug used in the treatment of brain cancer, KXO2 is more efficacious and less toxic. KXO2 not only slows the rate of tumor progression in all treated mice, it has cured tumors in a significant percentage of treated animals. “The cures have been validated using MRI and the results are astounding”, said Dr. David Hangauer, Senior VP of Research and Development at Kinex Pharmaceuticals.
In 2009, The Company will complete pre-clinical pharmacology and toxicology studies that are required to file an Investigational New Drug (IND) application with the FDA. Phase 1 human studies are expected to start in late 2009/early 2010.
Kinex is developing Next Generation Cancer Drugs and among them is KX2-391 that is currently in late Phase 1 human clinical trials. Several Phase 2 trials are in the planning stage and are scheduled to be launched in mid-2009. Kinex has used its proprietary technology platform to design and synthesize non-ATP competitive kinase inhibitors; a new class of drugs that promise to deliver effective therapy with minimal side effects.
The Company’s pipeline is focused on kinase targets for cancer and immunological-based diseases.